Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Yorkshire life sciences firm Aptamer developing Ebola diagnostic test

Published

on

Business Live

The company is working on a potential rapid diagnostic test for the highly infectious Bundibugyo strain

Aptamer Group was launched in 2008.

Arron Tolley, CEO, Aptamer Group plc.(Image: Martin Avery Photography)

York life sciences business Aptamer has announced it has started developing a potential diagnostic test for Ebola. The company, which develops synthetic binders for the life sciences industry, is working on a potential rapid diagnostic test for the highly infectious Bundibugyo strain of the Ebola virus.

An outbreak of the strain started in the Democratic Republic of Congo and Uganda in May – the largest recorded outbreak of the rare strain – and the World Health Organization has declared both an epidemic and a public health emergency.

Advertisement

Fatality rates for the Bundibugyo strain of Ebola range from approximately 30% to 50%, depending on factors including virus strain, the quality of patient care quality, and how quickly it is picked up and treated. Early detection is critical to patient outcomes and outbreak containment.

Unlike the more common Zaire strain of Ebola, for which vaccines and treatments exist, current diagnostic tests struggle to rapidly and reliably identify Bundibugyo.

In a note to shareholders, Aptamer said its Optimer technology has previously demonstrated rapid responses in diagnostic applications to support the response to infectious disease outbreaks. During the COVID-19 pandemic, Aptamer developed SARS-CoV-2 binders that were successfully translated into lateral flow tests.

The firm says the global Ebola testing market was valued at $1.2bn in 2025 and is projected to grow from $1.3bn in 2026 to $2.3bn by 2033.

Advertisement

Within this, the market in North America dominated with a revenue share of 40.9% in 2025.

The new programme will aim to develop Optimer binders suitable for integration into rapid, field-compatible diagnostic tests for Bundibugyo Ebola and work has started immediately.

Dr Arron Tolley, chief executive officer of Aptamer Group, said: “Those following the Ebola outbreak in Sub-Saharan Africa will note the growing severity of the situation on both a human and economic level.

“The head of the Africa Centres for Disease Control and Prevention, Director-General Jean Kaseya, has warned that containing this outbreak could cost billions of dollars. A critical limiting factor in response is rapid, accurate diagnosis. Existing tests lack the sensitivity needed for timely detection in field settings.

Advertisement

“During COVID, our platform demonstrated its ability to deliver diagnostic tools at pace to respond to infectious disease outbreaks. We are now applying that capability to develop Optimers for specific proteins of the Bundibugyo strain. With development under way in our labs, I look forward to updating shareholders as the programme progresses.”

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

SpaceX Shares Rebound Above $150 After Data Center Lawsuit Recently Threatened Its $45 Billion Anthropic Deal

Published

on

Tesla CEO Elon Musk has a new title: Technoking

Shares of Space Exploration Technologies Corp. traded at $152.35 on Thursday, up $4.09, or 2.76 percent, recovering some ground after the stock briefly slid toward its initial public offering price earlier in the week following news that a lawsuit had forced the shutdown of a data center tied to a major artificial intelligence contract.

Note: This article is intended to provide factual context and does not constitute financial advice. Readers should consult a licensed financial advisor before making investment decisions.

SPCX shares fell as low as $150.55 during early trading Tuesday, coming close to slipping below the company’s original $135 listing price for a second time since the company’s public debut on June 12. According to TradingKey, the decline was tied to reports that a legal challenge had led to the shutdown of gas turbines powering SpaceX’s Colossus 2 data center, a facility central to a reported $45 billion contract with AI company Anthropic. The lawsuit raised questions about whether the disruption could jeopardize the underlying agreement, contributing to renewed selling pressure on the stock even as broader market sentiment toward technology shares remained mixed heading into the week.

The pullback came just as SpaceX was completing its formal addition to the Nasdaq-100 index on July 7, a milestone that marked the fastest such inclusion in the index’s history, occurring just 15 trading days after the company’s record-setting IPO. According to TradingKey’s analysis published around the time of the inclusion, SPCX was trading near $158 with a technical floor identified around $149, and the firm cautioned that historical precedent from other high-profile Nasdaq-100 additions, including Palantir and Strategy, showed both stocks peaking around their respective inclusion dates before experiencing significant pullbacks in the weeks that followed.

Advertisement

Despite the recent volatility, Wall Street sentiment toward SpaceX has remained largely constructive. According to TipRanks, SpaceX has received several buy ratings from major brokerages since officially joining the Nasdaq-100, and analysts currently characterize the stock as undervalued relative to its price. Morgan Stanley analyst Adam Jonas has continued to advocate a bullish case for the company, according to CNBC, while separate coverage from JPMorgan described the possibility of a future merger between SpaceX and Tesla, both led by Elon Musk, as “strategically coherent,” fueling continued speculation about the long-term structure of Musk’s broader corporate holdings.

Investor Cathie Wood’s ARK Invest has continued to make notable moves involving SpaceX shares in recent sessions. According to TipRanks, ARK Invest exchange-traded funds purchased 182,000 additional shares of SpaceX on Wednesday, extending a pattern of active portfolio adjustments the firm has made involving the stock since its public listing. Separately, options market activity has shown a moderately bearish tilt among traders in recent sessions, with notable put buying activity observed as shares traded in the mid-$140s earlier in the week.

Beyond the data center dispute, SpaceX has continued to generate a steady stream of corporate news since going public. The company’s newly integrated AI division, operating under the SpaceXAI banner following its merger with Elon Musk’s xAI earlier this year, announced this week that it was releasing its latest large language model, Grok 4.5, in partnership with AI coding company Cursor. SpaceX also moved bitcoin on-chain for the first time in six months on Tuesday, according to TipRanks, an $88 test transaction that ended a lengthy period of blockchain inactivity for the company and drew attention from cryptocurrency-focused analysts tracking corporate bitcoin holdings.

SpaceX’s broader business continues to span three primary segments. Its Space division designs, manufactures and launches reusable rockets, including the Falcon 9, Falcon Heavy and Starship vehicles, for both commercial and government customers, and conducts more orbital launches annually than any other launch provider in the world, including national space programs. Its Connectivity segment operates the Starlink satellite broadband network, which now includes approximately 9,600 satellites in low-Earth orbit delivering service to customers across more than 164 countries and territories. Its AI segment, formed through the xAI acquisition earlier this year, operates the Grok large language model, the X social media platform, and a growing footprint of AI computing infrastructure, including the Colossus data center system at the center of this week’s legal dispute.

Advertisement

The company’s customer base includes some of the largest institutional space and technology purchasers in the country, with NASA, the U.S. Space Force and the National Reconnaissance Office among its largest government clients. Elon Musk owns approximately 42 percent of SpaceX’s outstanding shares and controls roughly 85 percent of the company’s voting power through a structure of super-voting stock, giving him continued significant control over the company’s strategic direction even as it now trades as a public company.

Valuation remains a central point of debate among analysts covering the stock. According to Morningstar, SpaceX’s aggressively lofty valuation implies that investors will likely need to wait years, if not decades, for the company’s earnings to grow into its current market multiples, even as the firm acknowledged SpaceX’s dominant, decade-long lead over competitors in launch experience and payload volume. The company’s market capitalization stood at approximately $2.13 trillion as of the most recent trading data from TipRanks, reflecting the scale of investor interest in the stock despite its short public trading history.

SpaceX’s 52-week trading range, reflecting price movement since its IPO just weeks ago, spans from a low of $147.11 to a high of $225.64, according to TipRanks, illustrating the significant volatility that has characterized the stock’s brief time on public markets. The company has not yet announced a date for its first quarterly earnings report as a public company, an event analysts have identified as a key upcoming catalyst likely to provide further clarity on the durability of both its core launch and Starlink businesses and its rapidly expanding AI infrastructure segment.

With the data center dispute still developing and the broader Anthropic contract’s status not yet fully clarified in public disclosures, investors are likely to continue monitoring further updates on the legal proceedings, along with SpaceX’s ongoing execution across its space, connectivity and artificial intelligence businesses, as key factors shaping the stock’s trajectory in the weeks ahead following its historic entry into the Nasdaq-100 index.

Advertisement
Continue Reading

Business

Northern Technologies International Corporation (NTIC) Q3 2026 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript